Related Experiment Videos
Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C
1Department of Internal Medicine, Onomichi General Hospital, Japan.
Insights
Interferon therapy for chronic hepatitis C can cause cardiovascular adverse effects, including arrhythmia and heart disease, in 3.2% of patients. Monitoring is crucial during and after treatment due to unpredictable cardiac events.
Area of Science:
- Hepatology
- Cardiology
- Pharmacology
Background:
- Interferon is a standard treatment for chronic hepatitis C.
- Cardiovascular adverse effects of interferon are not well-documented.
- Understanding these cardiac risks is important for patient management.
Purpose of the Study:
- To investigate the clinical features of cardiovascular adverse effects during and after interferon therapy in chronic hepatitis C patients.
- To determine the incidence and types of cardiac complications associated with interferon treatment.
Main Methods:
- Prospective monitoring of 295 patients with chronic active hepatitis C undergoing interferon therapy.
- Follow-up for 1 year post-treatment to detect cardiovascular adverse effects.
- Analysis of clinical factors potentially related to adverse events.
Main Results:
- Cardiovascular adverse effects occurred in 10 out of 312 treatment courses (3.2%).
- Observed effects included arrhythmia (4), ischemic heart disease (4), and myocardial disease (2).
- No clinical factors, including prior cardiovascular disease, predicted these adverse events.
Conclusions:
- Cardiovascular adverse effects from interferon are frequent in chronic hepatitis C patients.
- These effects can manifest during and up to a year after therapy, unpredictably.
- Continuous patient monitoring, both during and after interferon treatment, is essential.
Abstract:
The therapeutic effects of interferon in chronic hepatitis C and many of its adverse effects have been well documented. However, there are only a few reports regarding its adverse effects on the cardiovascular system. The aim of this study was to clarify the clinical features of the adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. We monitored 295 patients with chronic active hepatitis C during 312 courses of interferon therapy and for 1 year after the end of treatment for the presence of cardiovascular adverse effects. We found 6 patients with cardiovascular adverse effects during interferon therapy and 4 more patients within 1 year after the end of therapy (10/312, 3.2%). The adverse effects of interferon on the cardiovascular system included arrhythmia (n = 4), ischemic heart disease (n = 4) and myocardial disease (n = 2). None of the clinical factors, including history of cardiovascular disease, were related to these cardiovascular adverse effects. In all instances the patient's condition improved after discontinuation of interferon and adequate therapy. The cardiovascular adverse effects of interferon occurred frequently in patients with chronic hepatitis C, even after the end of therapy and they were unpredictable. Thus, all patients undergoing interferon therapy should be monitored not only during but also after the end of treatment.